Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30281256 | 0.85 | TAS2R14 (0.50) | ALDH1A1MAPTMEN1KMT2ATEAD4 | |
| SCHEMBL31280141 | 0.85 | TAS2R14 (0.50) | ALDH1A1MAPTMEN1KMT2ATEAD4 | |
| SCHEMBL2279929 | 0.84 | MAOB (0.55) | ALDH1A1MAPTMEN1KMT2ATSHR | |
| SCHEMBL2590126 | 0.84 | ALDH1A1 (0.71) | ALDH1A1KMT2ARARARARBMAOB | |
| SCHEMBL17908054 | 0.81 | MEN1 (0.55) | ALDH1A1MAPTMEN1KMT2ATEAD4 | |
| SCHEMBL3301071 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTMEN1KMT2ATEAD4 | |
| SCHEMBL518632 | 0.80 | PIM1 (0.53) | MRGPRX4RARARARBPPARA | |
| SCHEMBL20491473 | 0.80 | KCNH2 (0.44) | ALDH1A1MAPTMEN1KMT2AMRGPRX4 | |
| SCHEMBL20491344 | 0.80 | KCNH2 (0.44) | ALDH1A1MAPTMEN1KMT2AMRGPRX4 | |
| SCHEMBL1051747 | 0.79 | CPS1 (0.63) | ALDH1A1MEN1KMT2ACPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4061803-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | Eisai R&D Management Co., Ltd. (JP) | 2022-09-28 | — | — | EP | disclosed |
| CN-114981247-A | Piperazine compounds for inhibiting CPS1 | 卫材R&D管理有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021102300-A1 | PIPERAZINE COMPOUNDS FOR INHIBITING CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-05-27 | — | — | WO | disclosed |
| US-9884063-B2 | Amido-substituted azole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| EP-3126337-A2 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-02-08 | — | — | EP | disclosed |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-8513251-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8435995-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885MAPT 4105/4885MEN1 3445/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885MAPT 4105/4885MEN1 3445/4885 |
| US-20170020886-A1 | AMIDO-SUBSTITUTED AZOLE COMPOUNDS | TNK1, TNNI3K, TNKS | ALDH1A1 4024/4885MAPT 4439/4885MEN1 270/4885 |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | ALDH1A1 1966/4885MAPT 4350/4885MEN1 3585/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | ALDH1A1 343/4885MAPT 4321/4885MEN1 3239/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885MAPT 4105/4885MEN1 3445/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885MAPT 4105/4885MEN1 3445/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | ALDH1A1 4279/4885MAPT 3573/4885MEN1 3089/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | ALDH1A1 334/4885MAPT 4144/4885MEN1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.